Pathogenesis and natural history of Machupo virus infection in nonhuman primates
The mammarenavirus Machupo virus (MACV) is the causative agent of Bolivian hemorrhagic fever (BHF) and is associated with high mortality rates in humans and nonhuman primates (NHPs). There are currently no approved vaccines or treatments to combat BHF. As there are eight genetically distinct lineages of MACV, medical countermeasures are needed to protect against all strains within these lineages. While rodent models have been developed for a few strains of MACV, NHPs most faithfully reproduce human disease. However, NHP models have only been described for two strains of MACV. Here, we assessed the pathogenic potential of two genetically distinct strains of MACV representing two different lineages in cynomolgus and/or African green monkeys (AGM). Both MACV strains caused severe multisystemic disease consistent with BHF, often resulting in fatality with the lineage III strain resulting in uniform lethality in both NHP species and the lineage VIII strain resulting in uniform lethality in AGM. Pathology was consistent among the MACV strains and NHP species with primary involvement of the gastrointestinal and lymphoid systems with the central nervous system showing variable but widespread dissemination of MACV antigen. Spatial proteomics showed that MACV antigen was most prevalent in neurons (MAP2+) and Purkinje cells (MAP2+/Calbindin+). Multi-omics assessment of circulating mRNA and proteins showed the overall phenotype of BHF was similar between species; however, the magnitude of the inflammatory response diverged at late timepoints. Overall, MACV infection of NHP recapitulated BHF in humans driven by a dysregulated innate response resulting in vascular inflammation and hemodynamic instability. IMPORTANCE: Machupo virus (MACV) is a deadly and understudied mammarenavirus that causes severe disease known as Bolivian hemorrhagic fever (BHF) with high mortality rates in symptomatic humans. MACV is transmitted to humans by contact with the vesper mouse and has significant outbreak potential. No licensed vaccine or antivirals against MACV exist. Well-characterized animal models are critically needed to test the efficacy of promising candidate medical countermeasures against MACV and to understand how MACV causes disease. Here, we developed several new nonhuman primate models that accurately reproduced human BHF. We utilized spatial proteomics to reveal specific cell types involved in MACV infection, including those within the central nervous system, and employed a multi-omics approach to reveal circulating mRNA and protein biomarkers driving fatal disease outcomes. Our comprehensive investigation of the response to MACV infection in a highly translational species can be exploited to develop new countermeasures to combat BHF.
Authors
- Krystle N. Agans (ORCID: https://orcid.org/0000-0002-7319-6935)
- Natalie S. Dobias (ORCID: https://orcid.org/0009-0000-7352-5885)
- Jacquelyn Turcinovic (ORCID: https://orcid.org/0000-0002-7669-223X)
- Abhishek N. Prasad (ORCID: https://orcid.org/0000-0002-4147-2077)
- Robert W. Cross (ORCID: https://orcid.org/0000-0001-7718-1522)
- Viktoriya Borisevich
- Karla A. Fenton (ORCID: https://orcid.org/0000-0002-5530-6969)
- Thomas W. Geisbert (ORCID: https://orcid.org/0000-0003-0858-1877)
- Daniel J. Deer (ORCID: https://orcid.org/0009-0005-4744-8560)
- Declan D. Pigeaud (ORCID: https://orcid.org/0000-0001-7130-6144)
- Antoinette Lona
- Rachel O'Toole
Institutions
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- mBio
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1128/mbio.02195-26
- Primary Topic
- Viral Infections and Vectors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Allergy and Infectious Diseases